Bluejay Diagnostics insider logs net BJDX share purchase

HRT Financial LP, a ten percent owner of Bluejay Diagnostics, Inc., reported mixed trading in the company’s common stock.

Rhea-AI Filing Summary

HRT Financial LP, a ten percent owner of Bluejay Diagnostics, Inc., reported mixed trading in the company’s common stock. On July 9, 2026, it executed an open-market purchase of 64,047 shares at $1.51 per share. On July 10, 2026, it made an open-market sale of 34,938 shares at $1.40 per share. After these transactions, HRT Financial LP directly held 92,055 shares of Bluejay Diagnostics common stock, reflecting a net increase of 29,109 shares over the two days.

Filing Explained

The completed trades leave the reporting person with 92,055 directly held common shares, without disclosing an issuer-level structural transaction.

A Form 4 reports an insider transaction within two business days, and the July 13, 2026 filing records two reported common-stock transactions dated July 9 and July 10. The disclosed structural effect is a change in the reporting person's direct common-stock holdings, which are 92,055 shares after the reported transactions.

The filing uses code P for the July 9 acquisition and code S for the July 10 disposition; under the supplied definitions, those codes mean an open-market purchase and an open-market sale. It reports 64,047 shares purchased at $1.51 and 34,938 shares sold at $1.40. No Rule 10b5-1 plan checkbox is shown, so the sale is a sale with no trading plan disclosed in this filing.

Insider Trade Summary

Net Buyer: 29,109 shares

Net Buy 2 txns

Insider HRT FINANCIAL LP

Role 10% Owner

Bought 64,047 shs ($97K)

Sold 34,938 shs ($49K)

Type	Security	Shares	Price	Value
Sale	Common Stock	34,938	$1.40	$49K
Purchase	Common Stock	64,047	$1.51	$97K

Holdings After Transaction: Common Stock — 92,055 shares (Direct)

Key Figures

Shares purchased: 64,047 shares Purchase price: $1.51 per share Shares sold: 34,938 shares +3 more

6 metrics

Shares purchased 64,047 shares Open-market purchase of common stock on July 9, 2026 at $1.51 per share

Purchase price $1.51 per share Price for 64,047-share common stock purchase on July 9, 2026

Shares sold 34,938 shares Open-market sale of common stock on July 10, 2026 at $1.40 per share

Sale price $1.40 per share Price for 34,938-share common stock sale on July 10, 2026

Net shares bought 29,109 shares Net buy across reported transactions, per transaction summary

Shares held after trades 92,055 shares Direct holdings of common stock following the July 10, 2026 sale

Key Terms

open-market purchase, open-market sale, ten percent owner

3 terms

open-market purchase financial

"it executed an open-market purchase of 64,047 shares at $1.51 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

open-market sale financial

"it made an open-market sale of 34,938 shares at $1.40 per share"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

ten percent owner regulatory

"HRT Financial LP, a ten percent owner of Bluejay Diagnostics, Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did HRT Financial LP report for BJDX?

HRT Financial LP reported a purchase of 64,047 BJDX shares at $1.51 on July 9, 2026 and a sale of 34,938 shares at $1.40 on July 10, 2026, resulting in a net share increase.

Did HRT Financial LP increase or decrease its BJDX holdings in this Form 4?

HRT Financial LP increased its BJDX holdings on a net basis by 29,109 shares. It bought 64,047 shares and sold 34,938 shares over two days, ending with 92,055 shares held directly.

What is HRT Financial LP’s ownership in Bluejay Diagnostics (BJDX) after these trades?

Following the reported transactions, HRT Financial LP directly holds 92,055 shares of Bluejay Diagnostics common stock. This position reflects its status as a ten percent owner as indicated in the filing.

At what prices did HRT Financial LP trade BJDX shares in this filing?

HRT Financial LP bought BJDX shares at $1.51 per share on July 9, 2026 and sold shares at $1.40 per share on July 10, 2026, both described as open-market transactions.

How many BJDX shares did HRT Financial LP buy and sell in this Form 4?

HRT Financial LP purchased 64,047 BJDX shares and sold 34,938 shares. According to the transaction summary, this produced a net buy of 29,109 shares over the reporting period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 03:14 PM Accepted by SEC EDGAR 07/13/2026 - 03:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HRT FINANCIAL LP

(Last) (First) (Middle)

3 WORLD TRADE CENTER, 175 GREENWICH STRE

76TH FLOOR

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bluejay Diagnostics, Inc. [ BJDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		P		64,047	A	$1.51	126,993	D
Common Stock	07/10/2026		S		34,938	D	$1.4	92,055	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Adam Nunes	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)